University of Calgary
Calgary, Alberta, T2N 1N4, Canada
NCT Number: NCT03049384
Cancer-related fatigue (CRF) is a common and distressing symptom of cancer and/or cancer treatment that can persist for months or years in cancer survivors. Exercise is beneficial for the management of CRF, and general exercise guidelines for cancer survivors are available. However, exercise interventions have not been tailored to alleviate CRF in fatigued cancer survivors, and thus the potential to alleviate CRF may not have been realized. The primary aim of this research is to investigate the effect of a traditional vs. tailored 12-week exercise intervention on self-reported CRF severity.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Calgary, Alberta, T2N 1N4, Canada
Background and Rationale
Approximately one-third of cancer survivors experience severe and persistent fatigue for a number of years post-treatment, but this distressing symptom is often under-treated by healthcare professionals due to a lack of mechanism-targeted interventions. The assessment of cancer-related fatigue (CRF) is reliant on subjective fatigue measurements such as self-report questionnaires. Less attention has been given to objective physiological measurements. However, there are well-established techniques which allow the assessment of neuromuscular fatigue and its peripheral and central origins which could be utilized in the study of CRF. Very few studies have considered these objective measures alongside self-report scales in the study of CRF and only two have used such techniques in cancer survivors. To date, no studies have investigated neuromuscular fatigue in whole body, dynamic activity as relevant to daily tasks (and involving the lower limb due to its functional relevance to locomotion). Novel testing developed in our laboratory could be used as part of a wider screening to develop individualized interventions to alleviate CRF. It is well accepted in the field that CRF is multidimensional and in addition to a potential neuromuscular component, the role of sleep disturbance may also be implicated. Interventions targeted at improving sleep quality are therefore warranted, and there is sound evidence for the efficacy of exercise interventions in particular for improving CRF in cancer survivors. As a non-pharmacological intervention, physical activity has the strongest evidence base for treating CRF. However, the mechanisms explaining the reduction of CRF with exercise are not understood. Due to the complex and multi-factorial nature of CRF, it would be of benefit to tailor exercise interventions to the specific deficits (in regards to neuromuscular mechanisms) or difficulties (for example sleep disturbance) experienced by the individual. Ultimately, mechanism-targeted exercise interventions could be translated to clinical rehabilitation programs and lead to an improved quality of for cancer survivors.
Research Question & Objectives
The primary aim of this research is to investigate the effect of a traditional vs. tailored 12-week exercise intervention on self-reported CRF severity.
Methods
Fatigued cancer survivors who have completed primary treatment ≥ 3 months and ≤ 5 years from enrollment will be randomly allocated to one of two treatment arms: traditional (active control) and tailored exercise. Participants in the traditional exercise group will engage in aerobic and resistance exercise that is consistent with published recommendations. The tailored exercise group will be prescribed an intervention designed to address individual deficits (identified at baseline) that may be related to CRF. Participants will be assessed before and after the intervention for patient-reported outcomes, neuromuscular function and fatigue in response to whole-body exercise, sleep quantity and quality, physical activity levels, cardiorespiratory fitness and blood biomarkers.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The traditional exercise group will undertake a supervised exercise intervention involving aerobic exercise and light resistance training, in line with published guidelines for exercise in cancer survivors.
The tailored training group will be prescribed an individualized exercise intervention designed specifically to counteract deficits (e.g. neuromuscular) of difficulties (e.g. sleep disturbance) identified during pre-intervention testing.
Time frame: Baseline to after the 12-week intervention, at 6 month and 12 month follow up.
Self-report questionnaire for the assessment of cancer-related fatigue.
Time frame: Baseline and after the 12-week intervention.
General quality of life instrument intended for use with a variety of chronic illness conditions.
Time frame: Baseline and after the 12-week intervention, and during follow up (6 and 12 months).
Self-report questionnaire for the assessment of of nine common symptoms experienced by cancer patients.
Time frame: Baseline and after the 12-week intervention.
A reduction in maximal isometric force in the knee extensors measured before, during and after an intermittent cycling test.
Time frame: Baseline and after the 12-week intervention.
A reduction voluntary activation (using transcranial magnetic stimulation) measured measured before, during and after an intermittent cycling test.
Time frame: Baseline and after the 12-week intervention.
A reduction voluntary activation (using femoral nerve stimulation) measured before, during and after an intermittent cycling test.
Time frame: Baseline and after the 12-week intervention.
A reduction in potentiated quadriceps twitch force (from a high frequency doublet at 100 Hz) measured before, before, during and after an intermittent cycling test.
Time frame: Baseline and after the 12-week intervention.
Evoked from supra-maximal stimulation of the femoral nerve and measured before, during and after an intermittent cycling test.
Time frame: Baseline and after the 12-week intervention.
Evoked from supra-maximal stimulation of the femoral nerve and measured before, during and after an intermittent cycling test.
Time frame: Baseline and after the 12-week intervention.
Evoked from supra-maximal stimulation of the femoral nerve and measured before, during and after an intermittent cycling test.
Time frame: Baseline and after the 12-week intervention.
Normalized to the maximal M-wave and measured before, during and after an intermittent cycling test.
Time frame: Baseline and after the 12-week intervention.
Normalized to the maximal M-wave and measured before, during and after an intermittent cycling test.
Time frame: Baseline and after the 12-week intervention.
Normalized to the maximal M-wave and measured before, during and after an intermittent cycling test.
Time frame: Baseline and after the 12-week intervention.
Evoked from TMS and measured (from stimulation artifact to the continuous resumption of EMG) before, during and after an intermittent cycling test.
Time frame: Baseline and after the 12-week intervention.
Root mean square of the EMG signal during an MVC, measured before, during and after an intermittent cycling test.
Time frame: Baseline and after the 12-week intervention.
The mean difference between lowest and highest activity period, recorded with actigraphy.
Time frame: Baseline and after the 12-week intervention.
Time of day of the highest estimated level of wake, recorded by actigraphy.
Time frame: Baseline and after the 12-week intervention.
Mean level of activity over 24 hours, recorded with actigraphy.
Time frame: Baseline and after the 12-week intervention.
the degree of regularity of the rest-activity patterns on individual days in the 24 h environment, recorded with actigraphy.
Time frame: Baseline and after the 12-week intervention.
the fragmentation of periods of rest and activity, recorded with actigraphy.
Time frame: Baseline and after the 12-week intervention.
The mean activity counts in the least active 5 h period in the average 24 h pattern) recorded with actigraphy.
Time frame: Baseline and after the 12-week intervention.
The central time of the L5 period, usually referring to the through of the activity period), recorded with actigraphy.
Time frame: Baseline and after the 12-week intervention.
Amount of activity during wake, recorded with actigraphy
Time frame: Baseline and after the 12-week intervention.
Amount of activity during sleep periods, recorded with actigraphy
Time frame: Baseline and after the 12-week intervention.
Percentage of activity per epoch for wake and sleep, recorded with actigraphy.
Time frame: Baseline and after the 12-week intervention.
Time spent between the moment subject turn off the light to sleep and the moment he gets up, recorded with actigraphy.
Time frame: Baseline and after the 12-week intervention.
Time spent asleep during the night, recorded with actigraphy.
Time frame: Baseline and after the 12-week intervention.
Time spent awaken during the night, recorded with actigraphy.
Time frame: Baseline and after the 12-week intervention.
Time to fall asleep, recorded with actigraphy.
Time frame: Baseline and after the 12-week intervention.
Ratio between the time spent asleep and the total duration of sleep period, recorded with actigraphy.
Time frame: Baseline and after the 12-week intervention.
Indication of the sleep quality based on movement during night, recorded with actigraphy.
Time frame: Baseline and after the 12-week intervention.
Blood count, catecholamines, serotonin, cortisol, inflammatory markers and markers of oxidative stress.
Time frame: Baseline and after the 12-week intervention.
Self-report questionnaire for the assessment of health-related quality of life, specific to cancer type.
Time frame: Baseline and after the 12-week intervention.
Self-report questionnaire for the assessment of social support.
Time frame: Baseline and after the 12-week intervention.
Self-report questionnaire for the assessment
Time frame: Baseline, after the 12-week intervention, and during follow up (6 and 12 months).
Self-report questionnaire for the assessment of leisure time physical activity.
Time frame: Baseline and after the 12-week intervention.
Self-report questionnaire for the assessment of insomnia severity.
Time frame: Baseline and after the 12-week intervention.
Self-report questionnaire for the assessment of pain.
Time frame: Baseline and after the 12-week intervention.
The highest 30 second average oxygen uptake measured during an an incremental cycling test.
Time frame: Baseline and after the 12-week intervention.
Ultrasound measurement of the vastus lateralis and rectus femoris.
Time frame: Baseline and after the 12-week intervention.
Variation in the time interval between heartbeats.
Time frame: Baseline and after the 12-week intervention.
Measured using dual energy X-ray absorptiometry (DXA).
Time frame: Baseline and after the 12-week intervention.
Measured using dual energy X-ray absorptiometry (DXA).
Time frame: Baseline and after the 12-week intervention.
Measured using dual energy X-ray absorptiometry (DXA).
University of Calgary
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07693985
Adherence Interventions, Behavior
Valencia, Spain
View Trial DetailsNCT07682285
Cancer-related Fatigue, Carcinoma
Taipei, Taiwan
View Trial DetailsNCT03314805
Acquired agranulocytosis, Breast Diseases
Kaohsiung City, Taiwan
View Trial DetailsNCT07582666
Affect (Mental Function), Anxiety
Bellinzona, Canton Ticino, Switzerland
View Trial Details